Fulcrum Therapeutics
FULC
121 hedge funds and large institutions have $402M invested in Fulcrum Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 46 increasing their positions, 25 reducing their positions, and 36 closing their positions.
1,315% more call options, than puts
Call options by funds: $27.2M | Put options by funds: $1.92M
84% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 25
6.8% more ownership
Funds ownership: 97.48% → 104.28% (+6.8%)
4% less funds holding
Funds holding: 126 → 121 (-5)
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
29% less capital invested
Capital invested by funds: $570M → $402M (-$168M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.94M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.64M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.03M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.11M |
| 2 |
CAC
Cowen and Company
New York
|
-$5.68M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$4.17M |
| 4 |
Millennium Management
New York
|
-$3.75M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.63M |
FULC Hedge Fund Activity: Q2 2024 in Review
121 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2024, worth a combined $402M — down 29% from $570M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of FULC and 31 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 46 added.
The largest buyer was BlackRock, adding an estimated $24.7M. The largest seller was Adage Capital Partners, cutting an estimated $6.11M.
- 121 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2024, down from 126 in Q1 2024.
- Funds reported $402M of Fulcrum Therapeutics stock for Q2 2024, down 29% quarter-over-quarter.
- 31 funds opened new Fulcrum Therapeutics positions in Q2 2024 and 36 closed out, a net change of -5 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2024 was BlackRock, an estimated $24.7M added.
- The largest Fulcrum Therapeutics seller in Q2 2024 was Adage Capital Partners, an estimated $6.11M sold.
Based on aggregated 13F filings for Q2 2024.